What is Re-gen Active Lab?
Re-gen Active Lab operates as a trusted, FDA-registered tissue establishment, specializing in the development and manufacturing of biomolecules derived from human umbilical cord and amniotic membrane. The company is committed to producing high-quality, safe biomolecule-rich products, adhering to stringent donor screening and regulatory compliance. Their product portfolio encompasses a wide range of naturally occurring biomolecules, including exosomes, proteins, and growth factors, all produced under controlled environmental conditions. Re-gen Active Lab collaborates with AABB-accredited cord banks, prioritizing safety, consistency, and quality in its regenerative science endeavors.
How much funding has Re-gen Active Lab raised?
Re-gen Active Lab has raised a total of $2.3M across 2 funding rounds:
Debt
$24K
Other Financing Round
$2.3M
Debt (2021): $24K with participation from PPP
Other Financing Round (2024): $2.3M, investors not publicly disclosed
What's next for Re-gen Active Lab?
The recent major strategic investment signals a pivotal growth phase for Re-gen Active Lab. This capital infusion is expected to accelerate the company's research and development initiatives, enhance its manufacturing capabilities, and potentially expand its market reach. The focus on biomolecules derived from umbilical cord and amniotic membrane positions Re-gen Active Lab to capitalize on the growing demand for advanced regenerative therapies and innovative medical treatments.
See full Re-gen Active Lab company page
